Riken Corporation

Kabushikikaisha Kenwood

Chiba University

Japan Bcg Laboratory

Ambicion Co., Ltd.

Masaru Taniguchi

Hiroshi Watarai

Kenji Mori

Takuya Tashiro

Masao Shiozaki

Ryusuke Nakagawa

Ken-ichi Fuhshuku

Toshinori Nakayama

Yasuyuki Ishii

Shin-ichiro Fujii

Haruhiko Koseki

Risa Nozawa

Tomokuni Shigeura

Shigetoshi Horiguchi

Keigo Hanada

Minako Aihara

Takashi Naka

Ikuya Yano

Kenichiro Seino

Ken-ichiro Seino

Yoshitaka Okamoto

Shin-Ichiro Fujii

Ken-Ichi Fuhshuku

Ken-Ichiro Seino

The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-&#x3b3; production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.

Technology for efficient activation of NKT cells

The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the &#x3b1;-chain region of the T cell receptor gene rearranged to uniform V&#x3b1;-J&#x3b1; in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the &#x3b1;-chain region of a T cell receptor (TCR) gene has been rearranged to uniform V&#x3b1;-J&#x3b1;. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.

Immunotherapy using allo-NKT cells, cells for immunotherapy in which alpha chain of t-cell receptor (TCR) gene has been rearranged to uniform V&#x3b1;-J&#x3b1;, and banking of NKT cells derived from said cells

The invention provides a compound effective as an antitumor active agent or vaccine adjuvant and an intermediate useful for the synthesis of the compound, as well as production methods thereof, and a medicament containing the novel compound. The compound is a carbamate glycolipid represented by the formula (I) wherein each symbol is as defined herein. The invention also provides a dendritic cell pulsed with the glycolipid.

Carbamate glycolipid and use thereof

The invention provides a compound represented by the formula (I) wherein Ris a hydrogen atom or a hydroxyl group; two Rare the same or different and each is a hydrogen atom or a hydroxyl group; Ris a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and Ris a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof.

Hydroxylated KRN7000 analogue and use thereof

A liposome containing a regulatory cell ligand such as &#x3b1;-galactosyl ceramide or &#x3b2;-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Drug having regulatory cell ligand contained in liposome

To provide a method of efficiently delivering cells having an anti-tumor activity to tumor tissues to evoke a stronger anti-tumor reaction, and a method of providing a more effective tumor regression effect, both in a cellular immunotherapy for cancer utilizing cells having an anti-tumor activity or antigen presenting cells for activating cells capable of exhibiting an anti-tumor activity. Provided are: a method of treating head and neck cancer, comprising administering an anti-cancer cell composition containing NKT cells activated in vitro with an NKT cell ligand into the tumor-feeding artery, and administering an NKT cell-stimulating agent containing antigen presenting cells treated with an NKT cell ligand through the upper respiratory tract mucous membrane; a use, in anti-cancer treatment of head and neck region, of the anti-cancer cell composition and the NKT cell-stimulating agent; a kit comprising the anti-cancer cell composition and the NKT cell-stimulating agent; and the anti-cancer cell composition.

Use of anti-cancer cell composition for treatment of head and neck cancer, which is intended to be administered to nutrient artery of tumor

Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the &#x3b1;-chain region of the T cell antigen receptor gene rearranged to uniform V&#x3b1;-J&#x3b1; in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell having TCR&#x3b1; rearranged to NKT-TCR (NKT-iPS cell), obtained by contacting a somatic cell, such as an NKT cell, having the &#x3b1;-chain region of the T cell antigen receptor gene rearranged to uniform V&#x3b1;-J&#x3b1; in an NKT cell receptor-specific way, with nuclear reprogramming factors, isolated NKT cells obtained by differentiating the iPS cell ex vivo (iPS-NKT cell), a method of generating CD4/CD8-double positive NKT cells (DP-NKT cells) and mature NKT cells from NKT-iPS cells by altering the combination of feeder cells and/or cytokines, a method of expanding the iPS-NKT cells, and an NKT cell cytotherapy agent comprising NKT cells activated with &#x3b1;-galactosyl ceramide (&#x3b1;-GalCer), or iPS-NKT cells, and &#x3b1;-GalCer in combination.

Generating a mature NKT cell from a reprogrammed somatic cell with a T-cell antigen receptor &#x3b1;-chain region rearranged to uniform Va-Ja in a NKT-cell specific way

A compound represented by the following formula (1): wherein Ris an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, Ris a Chydrocarbon group optionally having substituent(s), Ris a hydrogen atom or a Chydrocarbon group optionally having substituent(s), Ris a Chydrocarbon group optionally having substituent(s), X is an oxygen atom or &#x2014;CH&#x2014;, and Y is &#x2014;CH&#x2014;, &#x2014;CH(OH)&#x2014; or &#x2014;CH&#x2550;CH&#x2014;, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-&#x3b3; of NKT cells.

Synthetic glycolipid and use thereof

The invention provides esterified &#x3b1;-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein Ris a hydrocarbon group having a carbon number of 1 to 30, Ris a hydrocarbon group having a carbon number of 1 to 20, Ris a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, Rand Rare the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or Rand Rin combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.

Esterified &#x3b1;-galactosylceramide

The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like. The glycolipid is represented by the formula (1) or a salt thereof 

Glycolipid and use thereof

The invention provides a method of screening a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, comprising using an IL-17RB positive NKT cell, as well as a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, containing a substance capable of inhibiting or eliminating the Th2 cell-like function of an IL-17RB positive NKT cell as an active ingredient.

Methods for treating allergic airway inflammation, airway hypersensitivity, and eosinophilia

The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.

Pseudoglycolipid and use thereof

An encoder encodes sound data and the like to generate a binary signal. A mapper converts the binary signal into a four-level symbol and outputs the four-level symbol. A base band filter includes a root raised cosine filter and a sinc filter. The base band filter blocks a predetermined frequency component of a symbol to shape the symbol into a waveform signal and outputs the waveform signal shaped. An FM modulator transmits a signal subjected to FM modulation according to a magnitude of an amplitude of a waveform signal to a receiving unit. When a symbol of &#xb1;3 is outputted from the mapper, a frequency shift of a signal transmitted from the FM modulator has a predetermined value in a range of &#xb1;0.822[kHz] to &#xb1;0.952[kHz]. This makes it possible to provide a modulating apparatus, a mobile communication system, a modulating method, and a communication method that use a modulating method that can conform to the FCC rule to be enforced in 2005 without using a linear power amplifier.

Modulating apparatus, mobile communication system, modulating method, and communication method

The present invention relates to a compound represented by the following formula (1') wherein R is an aldopyranose residue, Ris a C2-18 hydrocarbon group optionally having substituent(s), Ris an acyl group, X is an oxygen atom, a sulfur atom or &#x2014;NH&#x2014;, and p is an integer of 0-4, or a salt thereof. The compound of the present invention has a specific immunoregulatory ability, and is useful for the prophylaxis or treatment of autoimmune diseases and the like.

Growing community of inventors

Yokohama, Japan

Masaru Taniguchi